These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21595600)

  • 1. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation.
    Jordan SC; Toyoda M; Vo AA
    Expert Rev Clin Immunol; 2011 May; 7(3):341-8. PubMed ID: 21595600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin a natural regulator of immunity and inflammation.
    Jordan SC; Toyoda M; Vo AA
    Transplantation; 2009 Jul; 88(1):1-6. PubMed ID: 19584672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients.
    Jordan SC; Toyoda M; Kahwaji J; Vo AA
    Am J Transplant; 2011 Feb; 11(2):196-202. PubMed ID: 21219579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose intravenous immunoglobulin treatment: mechanisms of action.
    Boros P; Gondolesi G; Bromberg JS
    Liver Transpl; 2005 Dec; 11(12):1469-80. PubMed ID: 16315304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection.
    Jordan SC; Vo AA; Toyoda M; Tyan D; Nast CC
    Pediatr Transplant; 2005 Apr; 9(2):155-61. PubMed ID: 15787786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifiers of complement activation for prevention of antibody-mediated injury to allografts.
    Hughes PD; Cohney SJ
    Curr Opin Organ Transplant; 2011 Aug; 16(4):425-33. PubMed ID: 21681097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients.
    Jordan SC; Tyan D; Czer L; Toyoda M
    Pediatr Transplant; 1998 May; 2(2):92-105. PubMed ID: 10082441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of immunoglobulins activity].
    Kowalczyk D
    Pol Merkur Lekarski; 2011 Jun; 30(180):397-9. PubMed ID: 21751546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approaches to treatment of antibody-mediated rejection.
    Jordan SC; Vo AA; Tyan D; Nast CC; Toyoda M
    Pediatr Transplant; 2005 Jun; 9(3):408-15. PubMed ID: 15910400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients.
    Jordan SC; Peng A; Vo AA
    Contrib Nephrol; 2009; 162():13-26. PubMed ID: 19001810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravenous polyclonal immunoglobulins (IVIG): what use in transplantation?].
    Haymann JP; Glotz D
    Nephrologie; 1999; 20(3):139-43. PubMed ID: 10418003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients.
    Duronio A; Bajjoka I; Hsaiky L; Parasuraman R
    Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desensitized renal transplant recipients show reduced cellular responses to in vitro challenge.
    Kimball P; King A
    Transplant Proc; 2006 Dec; 38(10):3416-7. PubMed ID: 17175290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the cellular immune system by intravenous immunoglobulin.
    Tha-In T; Bayry J; Metselaar HJ; Kaveri SV; Kwekkeboom J
    Trends Immunol; 2008 Dec; 29(12):608-15. PubMed ID: 18926775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desensitization: achieving immune detente.
    Zachary AA; Eng HS
    Tissue Antigens; 2011 Jan; 77(1):3-8. PubMed ID: 21155718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.
    Sibéril S; Elluru S; Negi VS; Ephrem A; Misra N; Delignat S; Bayary J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Transfus Apher Sci; 2007 Aug; 37(1):103-7. PubMed ID: 17765663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
    Emmi L; Chiarini F
    Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.